论文部分内容阅读
目的:比较联合应用头孢曲松和阿奇霉素与单用头孢曲松治疗社区获得性肺炎的疗效及不良反应。方法:将362例社区获得性肺炎患者随机分成头孢曲松联合阿奇霉素组(治疗组)和单用头孢曲松组(对照组),治疗8天后,观察两者的临床疗效和不良反应。结果:治疗组181例,痊愈127例(70.1﹪),好转46例(25.4﹪),总有效率95.5﹪,不良反应发生率6.6﹪;对照组181例,痊愈82例(45.3﹪),好转27例(14.9﹪),总有效率60.2﹪,不良反应发生率3.9﹪。2组临床疗效有统计学差异(P<0.05),不良反应无统计学差异(P>0.05)。结论:头孢曲松联合应用阿奇霉素治疗社区获得性肺炎临床疗效优于单用头孢曲松,是社区获得性肺炎初始经验治疗的良好选择。
Objective: To compare the efficacy and side effects of ceftriaxone and azithromycin with ceftriaxone alone in the treatment of community-acquired pneumonia. Methods: 362 patients with community-acquired pneumonia were randomly divided into ceftriaxone plus azithromycin group (treatment group) and ceftriaxone alone group (control group). After 8 days of treatment, the clinical efficacy and adverse reactions were observed. Results: The treatment group of 181 cases, cured 127 cases (70.1%), 46 cases of improvement (25.4%), the total effective rate was 95.5%, the incidence of adverse reactions 6.6%; control group of 181 patients, 82 cases were cured (45.3% 27 cases (14.9%), the total effective rate 60.2%, the incidence of adverse reactions 3.9%. The clinical efficacy of the two groups was statistically significant (P <0.05), no significant difference in adverse reactions (P> 0.05). Conclusion: The clinical efficacy of ceftriaxone combined with azithromycin in the treatment of community-acquired pneumonia is better than that of ceftriaxone alone, which is a good choice for the initial experience-based treatment of community-acquired pneumonia.